FDAnews
www.fdanews.com/articles/132335-fda-panel-turns-down-avodart-proscar-for-prostate-cancer-prevention

FDA Panel Turns Down Avodart, Proscar for Prostate Cancer Prevention

December 2, 2010
An FDA advisory committee has turned down GlaxoSmithKline (GSK) and Merck’s hopes of gaining approval for, respectively, Avodart and Proscar, as preventive treatments for prostate cancer. The agency’s Oncologic Drugs Advisory Committee Wednesday voted 17–0 on Avodart (dutasteride) and 14–2 on Proscar (finasteride) that clinical trials did not support expanding the use of the drugs. One panel member abstained from the first vote and two members abstained from the second.
Drug Industry Daily